2022
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022, 163: 608-619. PMID: 35679950, DOI: 10.1053/j.gastro.2022.05.055.Peer-Reviewed Original ResearchConceptsEradication rateHelicobacter pylori infectionTriple therapyDual therapyPylori infectionProton pump inhibitor-based triple therapyTreatment-emergent adverse eventsInhibitor-based triple therapyPotassium-competitive acid blockerEfficacy of vonoprazanH pylori eradicationPhase 3 trialOverall study populationAmoxicillin-resistant strainsClarithromycin-resistant strainsH pylori infectionTreatment-naïve adultsPylori eradicationAdverse eventsSecondary outcomesPrimary outcomeStandard treatmentClinical trialsStudy populationAcid blocker
1996
Medical Treatment of Peptic Ulcer Disease: Practice Guidelines
Soll A, Achord J, Bozymski G, Brooks S, Lanza F, Lyon D, Meyer G, Reinus J, Schuster M, Achord J, Ofman J, Glassman P, Laine L, Tytgat G, Walsh J, Graham D, Peterson W. Medical Treatment of Peptic Ulcer Disease: Practice Guidelines. JAMA 1996, 275: 622-629. DOI: 10.1001/jama.1996.03530320046033.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNonsteroidal antiinflammatory drugsRefractory ulcersUlcer patientsPeptic ulcerSuccessful H pylori eradicationConventional maintenance therapyConventional ulcer therapyH pylori eradicationPractice Parameters CommitteeUse of aspirinPeptic ulcer diseaseH pylori infectionAmerican Gastroenterological AssociationMaintenance therapyNSAID usePylori eradicationAntibiotic regimenSymptom reliefAntibiotic therapyUlcer diseaseRecurrence rateUlcer therapyConventional therapyPylori infectionDisease management approach